Oral Presentation Deep responses following treatment with loncastuximab tesirine in patients with relapsed/refractory including those with high-risk, TP53-altered Waldenström macroglobulinemia
Oral Presentation Loncastuximab Tesirine with Rituximab Induces Robust and Durable Complete Metabolic Responses in High-Risk Relapsed/Refractory Follicular Lymphoma
Oral Presentation Limited duration loncastuximab with rituximab induces high complete response rate in high-risk relapsed/refractory follicular lymphoma – A phase 2 study
Oral Presentation Long-Term Responses With Loncastuximab Tesirine: Updated Results From LOTIS-2, the Pivotal Phase 2 Study of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Oral Presentation Camidanlumab tesirine: updated efficacy and safety in an open-label, multicenter, phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL)
Oral Presentation Camidanlumab tesirine: updated efficacy and safety in an open-label, multicenter, phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL)
Oral Presentation Real‐World Effectiveness and Economic Impact Associated with Chimeric Antigen Receptor T‐cell Therapy Among Older Patients with Relapsed/Refractory Diffuse Large B‐Cell Lymphoma in US
Oral Presentation ADCT-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia A Phase 1 Trial
Oral Presentation Camidanlumab tesirine efficacy and safety in an open-label, multicenter, Phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL)
Oral Presentation LOTIS-2 follow-up analysis: Updated results from a Phase 2 study of loncastuximab tesirine in relapsed or refractory diffuse large B-Cell lymphoma